27978-30-9

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-N-[4-(METHYLTHIO)PHENYL]ACETAMIDE is used as a chemical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure allows it to be a valuable component in the development of new medications and therapies for a range of health conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 2-CHLORO-N-[4-(METHYLTHIO)PHENYL]ACETAMIDE serves as a reagent, contributing to the creation of diverse chemical compounds for research and development purposes.
Used in Medicinal Chemistry Research:
2-CHLORO-N-[4-(METHYLTHIO)PHENYL]ACETAMIDE is also utilized in medicinal chemistry research, where it aids scientists in understanding the structure-activity relationships of potential drug candidates and in the design of novel therapeutic agents.

InChI:InChI=1/C9H10ClNOS/c1-13-8-4-2-7(3-5-8)11-9(12)6-10/h2-5H,6H2,1H3,(H,11,12)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 104-96-1 4-methylsulfanylaniline 

Relevant academic research and scientific papers

A colorimetric and fluorescence sensor based on biphenolic-dansyl derivative for specific fluoride ion detection

2?-(2-((4-(methylthio)phenyl)amino)-2-oxoethoxy)-[1,1?-biphenyl]-2-yl 5(dimethyl amino)naphthalene-1-sulphonate (1) was synthesised and used as a F? ion sensor. The selectivity of sensor 1 with various anions (F?, Cl?, Br

Sulfonamide-1,3,5-triazine-thiazoles: Discovery of a novel class of antidiabetic agents: Via inhibition of DPP-4

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a novel class of antidiabetic drugs used for treating type 2 diabetes mellitus. In the present study, a novel hybrid sulphonamide-1,3,5-triazine-thiazole derivatives were synthesized and characterized by 1H-NMR, 13C-NMR, FT-IR, mass spectroscopy and elemental analysis. The result showed that among the tested compounds, 8c was found to be a more potent inhibitor of DPP-4 (2.32 nM) than the alogliptin standard. Moreover, molecular docking results showed that ligand 8c was efficiently docked into the active site of the catalytic triad of Ser630, Asp708 and His740, encompassing both the S1 and S2 pocket with a CDOCKER interaction energy of 57.80. The in vitro results were further substantiated by in vivo blood glucose lowering effects in experimental subjects. The results of the investigation showed that compound 8c exhibited concentration-dependent improvement of glucose tolerance in ICR after oral administration. It has been also found that compound 8c (30 mg kg-1) showed a reduction in the area under the curve from 0 to 120 min [(AUC) 0-120 min] to 37.46%, which was found to be approximately similar to the hypoglycemic profile of alogliptin (standard). The activity of compound 8c was also investigated in STZ-induced diabetic rats where it showed a dose-dependent decrease in blood glucose levels together with an improvement in insulin levels probably via inhibition of DPP-4. The effect of compound 8c was also investigated on the lipid profile and antioxidant enzyme system.